Research company Aptahem reports no revenue during the second quarter, as planned. The operating loss was unchanged.Operating result was -1.4 million Swedish kronor (-1.4). Net result was -1.4 million Swedish kronor (-1.4).During the second quarter, Aptahem continued work on developing the drug candidate Apta-1, while keeping the organisation lean and cost controls strict.A new test batch from the collaboration with Hongene Biotech showed a purity of approximately 99 percent and improved production efficiency. According to the company, this strengthens the prospects for future clinical development, scale-up and partnerships, CEO Mikael Lindstam writes in the report. Aptahem is also seeking phase 2 collaborations with academic institutions for targeted studies in sepsis and related disease conditions. Confidentiality agreements have been signed, and dialogues and meetings with new parties are ongoing or planned.During the quarter, the rights issue was also completed. The company has additionally engaged Jarlen Capital for support regarding strategic and commercial opportunities for Apta-1, with compensation entirely linked to a successful outcome."Our overall strategy remains unchanged: to take Apta-1 forward towards patient studies and commercialisation through a combination of clinical development, external scientific validation and strategic partnerships. We are working methodically and with clear priorities to create the best possible conditions for the next value-creating step in Aptahem's development," Lindstam writes. Aptahem, SEK millionQ2-2026Q2-2025Net sales00Operating result-1.4-1.4Net result-1.4-1.4